The following is a list of what is included in the item above. Click the test(s) below to view what biomarkers are measured along with an explanation of what the biomarker is measuring.
Also known as: AFP and AFP-L3%, AlphaFetoprotein AFP and AFPL3
Also known as: CA 125 Tumor Marker, CA-125, Cancer Antigen 125, OC125, Ovarian Antigen
Also known as: CA 153, CA-Breast, Cancer Antigen 15-3, Cancer Antigen-Breast
Also known as: CA 199, Carbohydrate Antigen 19-9
Also known as: CA 2729, Cancer Ag 27-29
Also known as: Human Calcitonin, Thyrocalcitonin
Also known as: CBC, CBC includes Differential and Platelets, CBC/PLT w/DIFF, Complete Blood Count (includes Differential and Platelets)
NOTE: Ulta Lab Tests provides CBC test results from Quest Diagnostics as they are reported. Often, different biomarker results are made available at different time intervals. When reporting the results, Ulta Lab Tests denotes those biomarkers not yet reported as 'pending' for every biomarker the test might report. Only biomarkers Quest Diagnostics observes are incorporated and represented in the final CBC test results provided by Ulta Lab Tests.
Also known as: Carcinoembryonic Antigen
Also known as: DCP DesGammaCarboxyProthrombin, Des-gamma-carboxy prothrombin (DCP), PIVKA II (protein induced by vitamin K absence or antagonists II)
Also known as: Fecal Globin by Immunochemistry InSure, FOBT, InSure®, Occult Blood, Stool Blood, Stool Hemoglobin
Also known as: Chorionic Gonadotropin, hCG Total Quantitative, Human Chorionic Gonadotropin (Hcg), Quantitative , Human Chorionic Gonadotropin Total, Quantitative
Also known as: Lactate Dehydrogenase LD, LDH
Also known as: Anti-TPO, Antithyroid Antibodies, TgAb, Thyroglobulin Antibodies TgAb, Thyroglobulin Antibody (TgAb), Thyroid Antibodies, Thyroid Autoantibodies, Thyroid Peroxidase Antibody (TPOAb), Thyroid Stimulating Immunoglobulin, Thyroperoxidase Antibody, Thyrotropin Receptor Antibodies, TPOAb, TSH Receptor Antibody, TSI
The CA-4. Cancer Screening - Women panel contains 15 tests with 48 biomarkers.
Brief Description: The CA-4 Cancer Screening - Women panel is the most comprehensive diagnostic tool available for assessing cancer risk and monitoring the health of women potentially at high risk for various cancers. It encompasses an extensive range of biomarkers, each specifically chosen to detect early signs of cancer and monitor treatment progress or recurrence. This panel is essential for women with a significant family history of cancer, known genetic predispositions, or those who have had previous cancer diagnoses and need close surveillance.
Collection Method: Blood Draw and Fecal Collection
Specimen Type: Whole Blood, Serum, and Feces
Test Preparation: 12 Hours Overnight Fasting Required
The CA-4 Cancer Screening - Women panel is typically ordered for women with an elevated risk of developing cancer, either due to genetic factors, personal or family medical history, or specific symptoms that suggest cancer. This panel is also vital for ongoing monitoring in cancer survivors to detect recurrence or to evaluate the effectiveness of current treatment regimens. It provides detailed insights that guide clinical decisions, helping to personalize patient care based on specific cancer markers and other significant health indicators.
This panel incorporates a broad array of tests, each serving a critical role in cancer screening and health monitoring:
Alpha-Fetoprotein and AFP-L3: These markers are crucial for the detection and monitoring of liver cancer, providing insights into the nature of liver lesions.
Amylase: Elevated levels can indicate pancreatic disorders, including pancreatic cancer.
CA 125: A vital marker for ovarian cancer, used to monitor treatment response and check for recurrence.
CA 15-3: Primarily associated with breast cancer, it helps in monitoring treatment effectiveness and detecting metastasis.
CA 19-9: Useful for diagnosing and monitoring pancreatic cancer and other gastrointestinal cancers.
CA 27.29: Another marker for breast cancer, useful in assessing treatment response and detecting recurrence.
Calcitonin: An important marker for medullary thyroid cancer, used for both diagnosis and monitoring.
Complete Blood Count with Differential and Platelets: Offers a snapshot of overall health and can detect anemia or infection, which might be secondary to cancer or its treatment.
CEA: Typically elevated in colorectal cancer patients; also used to monitor other cancers.
Des-Gamma-Carboxy-Prothrombin: A specific marker for hepatocellular carcinoma, important for detection and monitoring.
Fecal Globin by Immunochemistry: Screens for colorectal cancer by detecting hidden blood in stool samples.
Gastrin: High levels can indicate Zollinger-Ellison syndrome, which may be associated with tumors in the pancreas or duodenum.
Total hCG Quantitative: Beyond pregnancy testing, elevated levels can indicate certain types of cancers.
Lactate Dehydrogenase: An indicator of tissue breakdown and tumor activity, valuable in assessing cancer progression or response to treatment.
Thyroglobulin Antibodies: Used to detect potential interference in thyroid cancer markers, aiding in the detection of recurrence.
This extensive panel helps detect and monitor a wide array of conditions:
Liver Cancer: Early detection through specific markers like AFP and DCP increases the chances for successful treatment.
Pancreatic and Gastrointestinal Cancers: Markers like amylase, CA 19-9, and gastrin provide crucial information for these often hard-to-diagnose cancers.
Ovarian and Breast Cancer: CA 125, CA 15-3, and CA 27.29 are essential for monitoring these common cancers in women, assessing treatment response and detecting recurrence.
Medullary Thyroid Cancer: Calcitonin is a specific marker for this type of cancer, vital for both diagnosis and monitoring.
Colorectal Cancer: Fecal Globin by Immunochemistry is an effective tool for early screening.
Healthcare professionals utilize the results from the CA-4 panel to:
Guide Clinical Decisions: Tailor treatment plans based on the specific cancer markers elevated, which can greatly improve patient outcomes.
Monitor Therapy and Disease Progression: Regular assessments with this panel help track the effectiveness of treatments and detect early signs of recurrence or metastasis.
The CA-4 Cancer Screening - Women panel stands as the pinnacle of cancer diagnostic tools for women, offering unmatched depth and breadth in its screening capabilities. This panel not only aids in the early detection of a variety of cancers but also plays a crucial role in monitoring treatment effectiveness and disease progression, ultimately enhancing the quality of care and improving survival rates.
We advise having your results reviewed by a licensed medical healthcare professional for proper interpretation of your results.